Growth Differentiation Factor 9 Supplementation Restores the Lipopolysaccharide‐Induced Negative Effects on Bovine Oocyte Developmental Competence
Molecular Reproduction and Development · 2026-04 · 93 (4)
DOI: 10.1002/mrd.70099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Reproduction and Development, online erschienen am 09.04.2026. Verfasst von Dragos Scarlet und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Veterinary Anatomy, Vetsuisse Faculty Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Lipopolysaccharides, Growth Differentiation Factor 9, Oocytes, In Vitro Oocyte Maturation Techniques. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The present work was financially supported with funds from the Institute of Veterinary Anatomy and Clinic of Reproductive Medicine, Vetsuisse Faculty, Universi….
Abstract (Originalsprache)
Growth differentiation factor 9 (GDF9) plays a key role in enhancing developmental competence and blastocyst yield during in vitro maturation (IVM). This study investigated whether GDF9 could counteract the harmful effects of lipopolysaccharide (LPS), a gram‐negative bacterial component, on bovine in vitro embryo production, while also examining related gene expression in cumulus cells and oocytes. We hypothesized that GDF9 may compensate for LPS through the NF‐κB pathway. Ovaries were collected from a slaughterhouse, and oocytes (≥ 50 per group per replicate) were matured under four conditions: control, GDF9, LPS, and GDF9 + LPS. After IVM, fertilization and culture were performed, with blastocyst development evaluated on Day 7. Cumulus cells and oocytes were analyzed for gene expression (RT‐qPCR), while IVM media were tested for progesterone and estradiol. Results showed that co‐treatment with GDF9 and LPS restored cumulus expansion, cleavage, blastocyst rate, and embryo quality compared with LPS alone ( p < 0.05), with no differences from controls. LPS increased mRNA levels of CXCL8 , TNFα , and TLR2 in cumulus cells ( p < 0.05), but candidate gene expression in oocytes and cumulus cells remained unaffected. Steroid concentrations and estradiol:progesterone ratios were similar across groups. In summary, GDF9 supplementation alleviates LPS‐induced impairment in bovine oocytes during IVM, though the underlying mechanisms remain unclear.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Veterinary Anatomy, Vetsuisse Faculty Zurich, Zurich, Switzerland.
- Clinic of Reproductive Medicine, Vetsuisse Faculty Zurich, Zurich, Switzerland.
- Veterinary Clinic for Reproductive Medicine and Neonatology, Justus-Liebig-University, Giessen, Germany.
- AgroVet-Strickhof, Vetsuisse Faculty, Lindau, Switzerland.
ORCID-Profile: Dragos Scarlet, Mariusz P Kowalewski
Förderung
- The present work was financially supported with funds from the Institute of Veterinary Anatomy and Clinic of Reproductive Medicine, Vetsuisse Faculty, Universi…
Zitieren
APA
Scarlet, D., Serbetci, I., Schuler, G., Bollwein, H., & Kowalewski, M. P. (2026). Growth Differentiation Factor 9 Supplementation Restores the Lipopolysaccharide‐Induced Negative Effects on Bovine Oocyte Developmental Competence. Molecular Reproduction and Development, 93(4). https://doi.org/10.1002/mrd.70099
Vancouver
Scarlet D, Serbetci I, Schuler G, Bollwein H, Kowalewski MP. Growth Differentiation Factor 9 Supplementation Restores the Lipopolysaccharide‐Induced Negative Effects on Bovine Oocyte Developmental Competence. Molecular Reproduction and Development. 2026;93(4). doi:10.1002/mrd.70099
BibTeX
@article{Scarlet2026,
author = {Scarlet, Dragos and Serbetci, Idil and Schuler, Gerhard and Bollwein, Heinrich and Kowalewski, Mariusz P},
title = {Growth Differentiation Factor 9 Supplementation Restores the Lipopolysaccharide‐Induced Negative Effects on Bovine Oocyte Developmental Competence},
journal = {Molecular Reproduction and Development},
year = {2026},
volume = {93},
number = {4},
doi = {10.1002/mrd.70099}
}
EUVIMED